KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare ConferenceBusiness Wire • 04/03/24
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference AmericasBusiness Wire • 03/18/24
KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for SebetralstatBusiness Wire • 03/12/24
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational UpdateBusiness Wire • 03/11/24
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference AmericasBusiness Wire • 03/08/24
KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive OfficerBusiness Wire • 03/07/24
KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma ConferenceBusiness Wire • 03/06/24
KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual MeetingBusiness Wire • 02/27/24
KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual MeetingBusiness Wire • 02/26/24
KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual MeetingBusiness Wire • 02/16/24
KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded WarrantsBusiness Wire • 02/15/24
KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsBusiness Wire • 02/14/24
KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade)Seeking Alpha • 02/14/24
KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary AngioedemaBusiness Wire • 02/13/24
KalVista: On Demand Oral Treatment For HAE Signifies Differentiated AdvancementSeeking Alpha • 01/03/24
KalVista Pharmaceuticals Announces Publication of First Oral Factor XIIa Data in Frontiers in PharmacologyBusiness Wire • 12/20/23
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational UpdateBusiness Wire • 12/07/23
KalVista Pharmaceuticals Presents Real-World Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & ImmunologyBusiness Wire • 11/14/23
KalVista Pharmaceuticals Announces Phase 3 KONFIDENT Trial Milestone AchievedBusiness Wire • 11/13/23